Philip D. Hall

Title
InstitutionMedical University of South Carolina
DepartmentCOP Clinical Pharmacy and Outcome Sciences - MUSC Campus
AddressP.O. Box MSC141
QF108C
280 Calhoun St.
Phone843-792-8979
Fax843-792-9081
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hall PD, Fish H, McBane S, Mercer J, Moreau C, Owen J, Policastri A, Rattinger GB, Srivastava SB, Thomas MC, Bradley-Baker LR. The Report of the 2018-2019 Professional Affairs Standing Committee: The Role of Educators in Pharmacy Practice Transformation. Am J Pharm Educ. 2019 12; 83(10):7596. PMID: 32001892.
      Citations:    
    2. Barkoulas T, Hall PD. Experience with dasatinib and nilotinib use in pregnancy. J Oncol Pharm Pract. 2018 Mar; 24(2):121-128. PMID: 29284357.
      Citations:    
    3. Smith MA, Bell HS, Kissack JC, Hall PD, Mackinnon GE, Lang WG. Report of the 2012-2013 standing committee on advocacy: advocacy tools and resources: a framework for increasing member engagement. Am J Pharm Educ. 2013 Dec 16; 77(10):S17. PMID: 24371356.
      Citations:    
    4. Hall PD, Dipiro JT, Rowen RC, McNair D. A continuous quality improvement program to focus a college of pharmacy on programmatic advancement. Am J Pharm Educ. 2013 Aug 12; 77(6):117. PMID: 23966720.
      Citations:    
    5. Teusink AC, Hall PD. Toxicities of gemcitabine in patients with severe hepatic dysfunction. Ann Pharmacother. 2010 Apr; 44(4):750-4. PMID: 20233917.
      Citations:    
    6. Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer. 2010 Feb; 19(2):231-7. PMID: 20069435.
      Citations:    
    7. Hall PD, Beagle KL, Garrett-Mayer E, Frankel AE. Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein. Anticancer Drugs. 2008 Nov; 19(10):1007-11. PMID: 18827566.
      Citations:    
    8. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy. 2006 Jun; 26(6):806-12. PMID: 16716134.
      Citations:    
    9. Hall PD, Sinha D, Frankel AE. Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy. Cancer Immunol Immunother. 2006 Aug; 55(8):928-32. PMID: 16645883.
      Citations:    
    10. Niedermeier DM, Frei-Lahr DA, Hall PD. Treatment of acute myeloid leukemia during the second and third trimesters of pregnancy. Pharmacotherapy. 2005 Aug; 25(8):1134-40. PMID: 16207105.
      Citations:    
    11. Liu TF, Hall PD, Cohen KA, Willingham MC, Cai J, Thorburn A, Frankel AE. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res. 2005 Jan 01; 11(1):329-34. PMID: 15671563.
      Citations:    
    12. Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother. 2005 Aug; 54(8):799-806. PMID: 15614527.
      Citations:    
    13. Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE. Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leuk Lymphoma. 2004 Aug; 45(8):1647-56. PMID: 15370220.
      Citations:    
    14. Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham MC, Pennell LK, Hogge DE, Kreitman RJ, Frankel AE. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif. 2004 Jan; 33(1):123-33. PMID: 14680969.
      Citations:    
    15. Frankel AE, Fleming DR, Hall PD, Powell BL, Black JH, Leftwich C, Gartenhaus R. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3555-61. PMID: 14506141.
      Citations:    
    16. Hall PD, Razzouk BI, Willoughby TE, McLean TW, Frankel AE. The majority of children and adolescents with acute myeloid leukemia have detectable anti-DT388-GMCSF IgG concentrations, but at concentrations that should not preclude in vivo activity. J Pediatr Hematol Oncol. 2002 Oct; 24(7):521-6. PMID: 12368687.
      Citations:    
    17. Kokko H, Hall PD, Afrin LB. Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion. Pharmacotherapy. 2002 Sep; 22(9):1188-92. PMID: 12222557.
      Citations:    
    18. Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002 May; 8(5):1004-13. PMID: 12006512.
      Citations:    
    19. Hall PD, Virella G, Willoughby T, Atchley DH, Kreitman RJ, Frankel AE. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin Immunol. 2001 Aug; 100(2):191-7. PMID: 11465948.
      Citations:    
    20. Hall PD, Willingham MC, Kreitman RJ, Frankel AE. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Leukemia. 1999 Apr; 13(4):629-33. PMID: 10214872.
      Citations:    
    21. Frankel AE, Hall PD, McLain C, Safa AR, Tagge EP, Kreitman RJ. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconjug Chem. 1998 Jul-Aug; 9(4):490-6. PMID: 9667951.
      Citations:    
    22. Hall PD, Kreitman RJ, Willingham MC, Frankel AE. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice. Toxicol Appl Pharmacol. 1998 May; 150(1):91-7. PMID: 9630457.
      Citations:    
    23. Frankel AE, Hall PD, Burbage C, Vesely J, Willingham M, Bhalla K, Kreitman RJ. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 1997 Nov 01; 90(9):3654-61. PMID: 9345050.
      Citations:    
    24. Tagge E, Harris B, Burbage C, Hall P, Vesely J, Willingham M, Frankel A. Synthesis of green fluorescent protein-ricin and monitoring of its intracellular trafficking. Bioconjug Chem. 1997 Sep-Oct; 8(5):743-50. PMID: 9327140.
      Citations:    
    25. Burbage C, Tagge EP, Harris B, Hall P, Fu T, Willingham MC, Frankel AE. Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells. Leuk Res. 1997 Jul; 21(7):681-90. PMID: 9301690.
      Citations:    
    26. McClay EF, McClay ME, Jones JA, Winski PJ, Christen RD, Howell SB, Hall PD. A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Cancer. 1997 Mar 01; 79(5):1037-43. PMID: 9041168.
      Citations:    
    27. Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health Syst Pharm. 1997 Jan 15; 54(2):185-9. PMID: 9117808.
      Citations:    
    28. Hall PD, Benko H, Hogan KR, Stuart RK. The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol. 1995 Nov; 23(12):1256-60. PMID: 7589279.
      Citations:    
    29. Hall PD, Lesher BA, Hall RK. Adjuvant therapy of node-negative breast cancer. Ann Pharmacother. 1995 Mar; 29(3):289-98. PMID: 7606076.
      Citations:    
    30. Hall PD. Immunomodulation with intravenous immunoglobulin. Pharmacotherapy. 1993 Nov-Dec; 13(6):564-73. PMID: 8302679.
      Citations:    
    Hall's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (221)
    Explore
    _
    Co-Authors (3)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _